Analysis of United States Patent 8,221,747
United States Patent 8,221,747, titled "Method and apparatus for determining a likelihood of a patient developing a specific disease," was granted on June 19, 2012, to Myriad Genetics, Inc. The patent claims a method for assessing the risk of developing breast cancer based on the analysis of specific genetic markers.
What Does United States Patent 8,221,747 Claim?
The core claims of US Patent 8,221,747 revolve around a method for determining the likelihood of a patient developing breast cancer. Specifically, the patent claims encompass:
-
Claim 1: A method for determining a likelihood of a patient developing breast cancer, comprising:
- obtaining a sequence of a human gene in a sample, wherein the human gene is one of BRCA1 and BRCA2; and
- comparing the sequence of the human gene with a reference sequence, wherein a difference between the sequence of the human gene and the reference sequence indicates a mutation, and wherein the presence of a mutation in BRCA1 or BRCA2 indicates a statistically significant increased risk of developing breast cancer.
-
Claim 13: An apparatus for determining a likelihood of a patient developing breast cancer, comprising:
- a data acquisition system configured to obtain a sequence of a human gene in a sample, wherein the human gene is one of BRCA1 and BRCA2; and
- a processor in communication with the data acquisition system, the processor configured to compare the sequence of the human gene with a reference sequence, wherein a difference between the sequence of the human gene and the reference sequence indicates a mutation, and wherein the presence of a mutation in BRCA1 or BRCA2 indicates a statistically significant increased risk of developing breast cancer.
The patent defines "difference" as including insertions, deletions, and substitutions of nucleotides. It also specifies that the sample can be blood, saliva, or tissue. The "statistically significant increased risk" is further elaborated to mean a risk that is at least 1.5 times greater than the average risk of breast cancer in the general population.
What is the Technological Context of This Patent?
US Patent 8,221,747 falls within the field of genetic diagnostics, specifically predictive genetic testing for hereditary cancer syndromes. The BRCA1 and BRCA2 genes are well-established tumor suppressor genes that play a crucial role in DNA repair. Mutations in these genes significantly increase an individual's lifetime risk of developing breast, ovarian, prostate, and other cancers.
The technological advancement claimed is the direct correlation of specific genetic variations (mutations) in BRCA1 and BRCA2 genes to an elevated risk of breast cancer. Prior to widespread genetic sequencing and the patenting of diagnostic methods, understanding the link between specific gene mutations and disease risk was less defined for clinical application. This patent sought to patent the method of identifying these mutations and their associated risk.
Myriad Genetics utilized this patent, along with others, to establish a near-monopoly on BRCA genetic testing for many years. Their BRACAnalysis® test became the dominant offering in the market, with the company asserting its patent rights against competitors.
What is the Patent Landscape for BRCA Gene Analysis?
The patent landscape surrounding BRCA gene analysis has been complex and highly litigated. US Patent 8,221,747 is one of several patents that Myriad Genetics held related to BRCA testing. Other key patents included those covering the genes themselves and methods of detecting mutations.
A landmark legal challenge to Myriad Genetics' patents, including those related to BRCA, was Association for Molecular Pathology v. Myriad Genetics, Inc. (2013). The Supreme Court ruled that isolated human genes are not patentable subject matter. This decision significantly impacted the patent landscape for diagnostic methods tied directly to isolated genes.
While the Supreme Court decision invalidated patents on the genes themselves, it did not directly invalidate patents claiming methods of analyzing those genes, especially if those methods involved more than just simple isolation and sequencing. However, the legal precedent set by the Supreme Court decision has led to greater scrutiny of method claims, particularly those that are seen as too broad or essentially claiming a natural phenomenon.
The landscape for BRCA testing has since become more competitive, with numerous laboratories offering testing services. This increased competition has driven down costs and improved accessibility for patients.
What are the Key Challenges and Criticisms of This Patent?
The primary challenge and criticism leveled against US Patent 8,221,747, and Myriad Genetics' broader patent portfolio, centered on access to genetic testing and its impact on patient care and medical research.
- Monopolization and Cost: Myriad Genetics' exclusive control over BRCA testing, enabled by patents like 8,221,747, led to high testing costs. This limited access for many patients, particularly those without comprehensive insurance coverage. Critics argued that this restricted the widespread adoption of a valuable diagnostic tool.
- Hindrance to Research: The exclusive licensing model employed by Myriad Genetics was criticized for potentially hindering independent research. Researchers might have faced challenges in conducting comparative studies or developing new analytical approaches without direct access to the proprietary testing methods or data.
- Impact on Medical Practice: The patent's enforceability meant that other clinical laboratories and researchers could not offer or independently validate BRCA testing without infringing on Myriad's patents. This created a bottleneck in the development and dissemination of diagnostic information.
- Patentability of Diagnostic Methods: The legal battles surrounding Myriad's patents raised fundamental questions about the patentability of diagnostic methods, particularly those that involve analyzing naturally occurring genetic material. The Supreme Court's ruling on gene patentability has influenced how such method patents are now viewed and challenged.
The patent was seen by many as an attempt to patent a diagnostic correlation that was becoming increasingly evident through scientific discovery, rather than a truly novel and inventive technological solution.
What is the Current Status and Impact of US Patent 8,221,747?
As of current knowledge, US Patent 8,221,747 expired on June 19, 2029. However, its impact on the genetic testing landscape was significant during its patent term.
The expiration of this patent, and others like it, has definitively opened the market for broader competition in BRCA gene analysis. Multiple laboratories now offer comprehensive genetic testing for BRCA1 and BRCA2 mutations, often at significantly lower price points than previously offered by Myriad Genetics. This increased competition has facilitated:
- Wider Patient Access: More individuals can now afford and access genetic testing, leading to earlier identification of at-risk individuals and proactive cancer management strategies.
- Technological Innovation: The competitive landscape has spurred innovation in testing methodologies, turnaround times, and the scope of genetic panels offered.
- Data Generation for Research: Increased testing volume by diverse providers has generated a larger pool of genetic data, which can be used for further research into cancer genetics and population-specific risk factors.
While the patent itself is no longer in force, its legacy is intertwined with the evolution of genetic testing law and the ongoing debate about balancing intellectual property rights with public health and scientific advancement. The legal challenges it faced, particularly the Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, Inc., have permanently reshaped the landscape of gene and diagnostic method patentability.
What are the Competitive Implications for Diagnostic Companies?
For diagnostic companies, the expiration of US Patent 8,221,747 and similar patents marks a critical shift.
- Increased Market Entry: The absence of patent restrictions allows new and existing diagnostic companies to freely offer BRCA gene analysis services. This intensifies competition based on price, quality, turnaround time, and customer service.
- Focus on Next-Generation Sequencing (NGS): With the patent barrier removed, companies are increasingly focusing on comprehensive NGS panels that include BRCA1 and BRCA2 alongside hundreds of other cancer-related genes. This offers a more holistic approach to cancer risk assessment.
- Differentiation Strategies: Companies will need to differentiate themselves beyond simply offering BRCA testing. This can involve developing proprietary algorithms for risk stratification, integrating genetic testing with clinical data, offering personalized genetic counseling services, or developing companion diagnostics for targeted therapies.
- Investment in Innovation: Without the protection of broad method patents, companies must continually invest in developing novel diagnostic technologies, improving assay performance, and enhancing data analysis capabilities to maintain a competitive edge.
- Partnerships and Collaborations: The more open landscape encourages partnerships between diagnostic providers, academic institutions, and pharmaceutical companies for research, clinical trials, and the development of targeted therapies based on genetic profiles.
The landscape is no longer defined by patent exclusivity but by technological leadership, operational efficiency, and the ability to provide integrated diagnostic solutions.
Key Takeaways
- US Patent 8,221,747 claimed a method for determining breast cancer risk by analyzing mutations in BRCA1 and BRCA2 genes.
- The patent was a key component of Myriad Genetics' near-monopoly on BRCA testing for many years.
- Legal challenges, notably the Supreme Court's decision in Association for Molecular Pathology v. Myriad Genetics, Inc., significantly impacted gene patentability and, by extension, method patents tied to isolated genes.
- The patent expired on June 19, 2029, leading to increased competition in the BRCA testing market.
- The expiration has broadened patient access, lowered costs, and spurred innovation in genetic diagnostics.
- Diagnostic companies now face a competitive market focused on technological advancement, service integration, and differentiation beyond basic gene analysis.
Frequently Asked Questions
-
What was the core innovation protected by US Patent 8,221,747?
The patent protected the method of analyzing BRCA1 and BRCA2 genes for mutations and correlating those mutations to an increased statistical likelihood of developing breast cancer.
-
Did the Supreme Court ruling in Association for Molecular Pathology v. Myriad Genetics, Inc. invalidate US Patent 8,221,747?
The Supreme Court ruling invalidated patents on isolated human genes, not directly method patents. However, the ruling shifted the legal landscape and led to increased scrutiny of method claims, impacting the enforceability and breadth of patents like 8,221,747 over time.
-
When did US Patent 8,221,747 expire?
The patent expired on June 19, 2029.
-
What is the current market for BRCA testing now that the patent has expired?
The market is now highly competitive, with numerous laboratories offering BRCA testing, often as part of broader genetic panels, leading to lower prices and greater accessibility.
-
How did Myriad Genetics enforce this patent?
Myriad Genetics used its patent portfolio, including US Patent 8,221,747, to prevent other laboratories from offering BRCA gene testing services, establishing a de facto monopoly for many years.
Citations
[1] United States Patent 8,221,747 B2. (2012, June 19). Method and apparatus for determining a likelihood of a patient developing a specific disease. Myriad Genetics, Inc.
[2] Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
